Biological Treatment for depression ERQ

Biological treatment

Refers to the use of medical or pharmacological interventions, most commonly SSRIs (Selective Serotonin Reuptake Inhibitors), which are believed to increase serotonin levels in the brain.

Monoamine hypothesis

Suggests that depression is caused by a chemical imbalance, particularly a deficiency in serotonin.

Aim of Kirsch et al. (2008)

To investigate the effectiveness of antidepressants (SSRIs) in treating Major Depressive Disorder by analyzing both published and unpublished clinical trial data submitted to the FDA.

Participants in Kirsch et al. (2008)

Clinical trial data from thousands of adult patients diagnosed with depression, collected from studies submitted to the U.S. Food and Drug Administration (FDA) for drug approval.

Procedure in Kirsch et al. (2008)

The researchers conducted a meta-analysis of both published and unpublished clinical trials of several antidepressants. The trials compared the effectiveness of antidepressants versus placebo in reducing depression symptoms.

Results of Kirsch et al. (2008)

The difference in symptom improvement between antidepressants and placebo was small and clinically significant only for patients with severe depression. In mild and moderate cases, the difference was not meaningful.

Conclusion of Kirsch et al. (2008)

Antidepressants like SSRIs are not significantly more effective than placebo in treating mild to moderate depression. Their benefits are more noticeable only in severely depressed patients.

Strengths of Kirsch et al. (2008)

Inclusion of unpublished studies reduced publication bias, increasing validity; large sample from multiple studies increased generalizability.

Limitations of Kirsch et al. (2008)

Focused only on short-term treatment; lacks long-term outcome data; clinical trial participants may not reflect the general population, limiting real-world applicability.

Kroenke et al (2001) - Aim

To compare the efficacy of paroxetine, sertraline and flouxetine in treating MDD

Kroenke et al (2001) - participants

573 Americans aged 19-96 with a mean age of 46, mainly caucasian sample (83% Caucasian, 13% black, 3% other). They had all been referred to the study by their clinician if they were suitable for treatment by antidepressants.

Kroenke et al (2001) - Procedure

A baseline assessment of their depressive symptoms was done using Mental Component Summary Score, and were then randomly assigned to one of the three medications. Patients were reassessed using MCSS at intervals of 1, 3, 6 and 9 months, and provided self-report data on sleep, memory, etc to be used in conjuction with MCSS.

Kroenke et al. (2001) - Results

All participants improved from their baseline in terms of depressive symptoms from an average of 74% to 36% at 3 months and 26% after 9 months. Improvements in MCSS scores were fairly consistent, with participants improving by 15 and 17 points.

Kroenke et al. (2001) - Conclusion

SSRIs may be effective in treating MDD, and the three medications tested have similar efficacy.

Kroenke et al (2001) - Strengths

Reliability increased by triangulation of data, both more objective and subjective self report measures show overall effectiveness of medication.

External validity by large age range, shows how SSRIs can be universal in their effects and administration.

Kroenke et al (2001) - Limitations

No placebo trial, so unable to evaluate whether placebo effect is present (and hence if the SSRIs are the cause of symptom improvement). This decreases the validity of the experiment and henceforth the application of SSRIs as it is questionable if the side effects are worth it if it is not truly effective.

Strength of biological treatment for depression

SSRIs are widely accessible, cost-effective, and fast-acting, allowing patients to manage their symptoms outside of hospital settings and regain autonomy. Don’t need a professional for every administration of the treatment.

Second strength of biological treatment for depression

Drug treatment has reduced the need for hospitalization, enabling more patients to live independently while managing their condition.

Limitations of biological treatment (SSRIs)

Reductionist, end up treating the symptoms rather than addressing the causes and other underlying problems. Many side effects, patients may not end up taking medication as perscribed. Placebo effect may be very strong and present, posing the question of if it is truly worth it considering all of the side effects.